WO2025224684 - COMPOSITIONS AND METHODS FOR PRODUCING ENGINEERED IMMUNE CELLS
National phase entry is expected:
Publication Number
WO/2025/224684
Publication Date
30.10.2025
International Application No.
PCT/IB2025/054308
International Filing Date
24.04.2025
Title **
[English]
COMPOSITIONS AND METHODS FOR PRODUCING ENGINEERED IMMUNE CELLS
[French]
COMPOSITIONS ET PROCÉDÉS DE PRODUCTION DE CELLULES IMMUNITAIRES MODIFIÉES
Applicants **
BIONTECH SE
BIONTECH CELL & GENE THERAPIES GMBH
Inventors
PANNEERSELVAM, Porkodi
JUNEJA, Vikram
XIE, Yushu
CHOUDHURY, Ishita
FOLEY, Kendra
SAHIN, Ugur
GRABUNDZIJA, Ivana
MONJEZI, Razieh
BILIC, Ilija
Priority Data
63/638,230
24.04.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 9750 | |
| EPO | Filing, Examination, Granting | 280535 | |
| Japan | Filing, Examination, Granting | 5598 | |
| South Korea | Filing, Examination, Granting | 15745 | |
| USA | Filing, Examination, Granting | 55740 |
Total:
367,368
Contact Us
Abstract[English]
The present disclosure provides compositions and methods for producing an engineered immune cell including a first nucleotide sequence encoding a T-cell receptor (TCR) and a second nucleotide sequence encoding a co-stimulatory receptor molecule. The present disclosure also provides methods for producing the engineered immune cells comprising a plurality of antigen specific T cells. The methods can be used to produce a therapeutically effective amount of antigen specific T cells within a short period of time. The compositions and methods provided herein can be used for the treatment of cancer.[French]
La présente divulgation concerne des compositions et des procédés de production d'une cellule immunitaire modifiée comprenant une première séquence nucléotidique codant pour un récepteur de lymphocytes T (TCR) et une seconde séquence nucléotidique codant pour une molécule réceptrice costimulatrice. La présente divulgation concerne également des procédés de production des cellules immunitaires modifiées comprenant une pluralité de lymphocytes T spécifiques d'un antigène. Les procédés peuvent être utilisés pour produire une quantité thérapeutiquement efficace de lymphocytes T spécifiques d'un antigène dans une courte période de temps. Les compositions et les procédés de la divulgation peuvent être utilisés pour le traitement du cancer.